Posted 12th July 2019 by Jane Williams
Numerous skincare brands incorporate lysates in their formulas. However, few brands are able to harness live and active bacteria in addition to the lysates. Neither is an easy task when it comes to formulation however, we can all acknowledge and appreciate the difficulty in working with live probiotics. So, what are the benefits and is this extra challenge worth the effort?
Posted 3rd July 2019 by Jane Williams
2019 may prove to be propitious in terms of meaningful improvements to the regulatory strictures facing agricultural biotech and biologically based products.
In a move that will hopefully lead to positive changes in the regulatory situation facing ag biotech products, on June 11, 2019, President Trump signed an Executive Order directing the heads of the U.S. Department of Agriculture (USDA), Environmental Protection Agency (EPA), and Food and Drug Administration (FDA) to take specific steps to streamline and improve the regulatory processes applicable to the products of agricultural biotechnology.
Posted 28th June 2019 by Jane Williams
The ECJ ruling on GMOs has raised pertinent issues. How will it impact on current and future research? What are the optimum routes to progressing plant research?
In light of the ruling, it was a good time to welcome experts in policy and regulatory affairs to the recent 7th Plant Genomics & Gene Editing Congress: Europe to explore these issues. We’re lucky to be able to share this presentation from the event for those that weren’t able to make it. Watch it here.
Posted 26th December 2018 by Jane Williams
It has been an eventful year for plant genomics: we’ve seen advancements in plant disease research, the sequencing of the wheat genome, which was finally achieved through a worldwide collaboration of researchers spanning 13 years, and the ruling on the legal status of gene-edited crops.
As 2018 draws to a close, we thought it was a good time to reflect. Here, we’ve collated our top articles of the year.
Posted 22nd August 2018 by Jane Williams
On 25 July 2018, the Court of Justice of the European Union, the EU’s highest court, issued a decision clarifying whether the EU would regulate products of innovative breeding techniques, like gene editing, under the EU’s Directive 2001/18, the principal EU law governing the regulation of GMOs.
Posted 20th August 2018 by Jane Williams
Degrading soil quality and increased interest in sustainable farming have caused the biostimulant market to go from strength-to-strength and it is expected to reach $4.14 billion by 2025.  Despite this, companies have expressed concerns that the regulation of biostimulants will hinder industry growth and the longevity of small companies and start-ups.
We spoke to Nick Moon, Global Regulatory Manager, Plant Impact, to discuss the regulation of biostimulants and its impact on industry.
Posted 10th August 2018 by Jane Williams
At the Partnerships in Biocontrol, Biostimulants, & Microbiome: Europe, Peter Jens, Director of Strategic Alliances at Koppert Biological Systems and CEO of AND Biopharma, discussed regulation from product to systems thinking.
He focused specifically on the way in which consumers and citizens have become more vocal on the quality of products, arguing that the current regulatory discussion is fated and different thinking is required.
Here, he explains what he means by ‘different’ kinds of thinking and how this could help unravel the regulatory quagmire of agrochemicals and agrobiologicals.
Posted 1st August 2018 by Jane Williams
Last week, the European Court of Justice ruled that gene-edited crops are equivalent to transgenic GMOs. The court ruling came as a surprise because it negates a preliminary opinion that was issued by the court’s Advocate General Michael Bobek in January 2018. This reactionary ECJ ruling might become the final nail in the coffin of the European Agbiotech sector and many scientists, including myself, are concerned that it will discourage the use of genome editing in agriculture.